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Disease-modi fy ing therapy fo r dement ia i s not 
ye t ava i lab le . A t p resent , t rea tment requ i res a 
comprehensive multidimensional approach, which 
i nc ludes 1 ) manag ing the d i sease , 2 ) t r ea t i ng 
the symptoms, 3) support ing the pat ient, and 4) 
supporting the caregiver. Pharmacological and non-
pharmacological interventions are equally important. 
Given early in the course of illness, these strategies help 
maintain or improve functioning and quality of life. 
Pharmacological Treatment
AD is a progressive degenerative brain disease. More 
than 200 agents have been investigated for disease-
modifying potential, but none was successful. The 
mainstay of current management of AD involves 
drugs that prov ide symptomat ic re l ie f . 1 The US 
Food and Drug Administration (FDA) have approved 
acetylcholinesterase inhibitors (AChEIs) and N-methyl-
D-aspartate (NMDA) receptor antagonist for the 
treatment of cognit ive symptoms in AD. For other 
drugs such as aspir in, steroids and non-steroidal 
anti-inflammatory drugs (NSAIDs), nicotine, hormone 
replacement and thiamine, the evidence for benefit on 
cognition is limited.2-5 For Ginkgo biloba, the results 
are conflicting.6 The best treatment involves concurrent 
app l i ca t ion o f bo th pharmaco log ica l and non-
pharmacological modalities.
Strategic Pharmacological Intervention 
for Dementia: Case Illustration
History
Madam Lam, aged 81 years old, presented with 
progressive deterioration of short-term memory for 3 
years, followed by recent problems in operating home 
electrical appliance, deranged cooking technique, and 
change in personality. She became argumentative, 
defensive and emotional when poor performances were 
pointed out by the others. Despite the cognitive deficit, 
she remained independent in self-care and was not 
depressed. 
Assessment
Mini-Mental State Examination (MMSE) score was 
below cut-off (18/30). Neurological examination was 
remarkable. Targeted blood tests did not reveal any 
abnormality. CT scan of brain showed cerebral atrophy. 
Diagnosis
Alzheimer’s disease (AD) of mild-to-moderate severity. 
Management
Oral rivastigmine 1.5 mg bd, gradual titration to 4.5 mg 
bd over 4 months.
Ms. LEE Nga Yee, 
Maggie
ROT, MMgt
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Treatment for Mild-to-Moderate AD
The AChEIs donepezil, rivastigmine, and galantamine 
are available in a variety of preparations including 
delayed-release pills, orodispersible tablets (donepezil) 
and patch form (rivastigmine).
The cholinergic hypothesis7 states that low levels 
of acetylcholine lead to cognitive decline. There is 
deficiency in cholinergic neurotransmission in AD. 
AChEIs inhibit the activity of acetylcholinesterase, an 
enzyme that breaks down acetylcholine at the synapse, 
resulting in increased availability of the neurotransmitter 
for binding to muscarinic and nicotinic receptors, and 
may improve memory and cognition in AD.
Statistically significant effects were shown on cognitive 
functions, activities of daily living and overall functioning 
with all three AChEIs, although the magnitude of effect is 
not large and not all patients benefit from the treatment. 
Some beneficial effects of AChEIs on behavioural 
symptoms were also described. A Cochrane database 
systemic review8 showed that AChEIs are efficacious 
for mild-to-moderate AD, and they are cost-effective. 
Despite the slight variations in the mode of action of the 
three AChEIs, there are no differences between them 
with respect to efficacy.9 
 
Strategic Pharmacological Intervention 
for Dementia: Case Illustration (Cont’d)
Progress
Madam Lam reported reduced appetite, weight loss of 
2.5 kg after taking rivastigmine for 4 months. Systemic 
enquiry and physical examination were unremarkable. 
Blood tests and stool for occult blood were normal. She 
declined oesophagogastroduodenoscopy examination. 
R i vas t igm ine was s topped in v i ew o f poss ib le 
gastrointestinal side effect.
She was not iced to have low mood attr ibuted to 
her daughter criticizing her overtly, and her son got 
unemployed recently. Antidepressant was started and 
she was encouraged to have more daytime and outdoor 
activities. Dementia day care services of Hong Kong 
Alzheimer’s Disease Association was introduced. 
Four weeks later, her mood and appetite improved. 
AChEIs was restarted with rivastigmine patch 4.6 mg/
d and dose stepped up to 9.5 mg/d in 1 month. Her 
bodyweight returned to normal level. 
All AChEIs have similar side effect profile. Patients most 
commonly complain of nausea, vomiting, insomnia 
and diarrhoea. They are more likely to occur at the 
commencement of therapy or when the dose of the 
agent is increased. These side effects are dose-related 
and tend to be transient. Introducing AChEIs at low 
doses, increasing the dose gradually, and administering 
the medication with meals may limit gastrointestinal side 
effects. 
Physicians should be aware of their direct anticholinergic 
and vagotonic actions, especially when prescribing for 
patients with cardiac conduction abnormalities and 
chronic obstructive pulmonary disease. 
It is advised to look for organic cause of weight loss 
and depression, before attributing to drug side effect. 
The patch formulat ion of r ivast igmine al lows the 
convenience of once-daily administration, and has fewer 
gastrointestinal adverse effects than its oral preparation.
Although memantine is approved for moderate to 
severe AD only, it is frequently prescribed off-label for 
mild AD. In an independent review of three clinical trials 
on memantine for mild AD, Schneider et al10 found no 
differences between memantine and placebo on any 
outcome for patients with mild AD.
Strategic Pharmacological Intervention 
for Dementia: Case Illustration (Cont’d)
Follow-up at 4 Years After Starting Treatment
Madam Lam became mostly home bound. She required 
assistance from her daughter in self-care and going 
outdoor. Her AD has progressed to severe stage, with 
an MMSE score of 11/30, compared with 18/30 4 
years ago. Memantine 10 mg/d was added on top of 
rivastigmine patch 9.5 mg/24 h.
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Treatment for Moderate-to-Severe AD
Apart from indication for mild-moderate AD, the US FDA 
has approved donepezil and rivastigmine transdermal 
system (patch) for severe stage of AD. Memantine 
was approved for the treatment of moderate to severe 
AD. Memantine is an NMDA receptor antagonist that 
prevent the excitotoxic effects of glutamate in the brain. 
In AD, glutamate receptors of the NMDA type are over-
activated, leading to neuronal damage and impairment 
of learning. Overall, patients with moderate-to-severe 
AD who received memantine performed better on 
behavioural measures than those treated with placebo.11
B o t h A C h E I s a n d m e m a n t i n e a r e l i c e n s e d a s 
monotherapy for AD. Theoretically, combining the two 
drugs could potentiate their benefits. While evidence 
for combination therapy with memantine and AChEIs 
is inconsistent, combination therapy is still regarded 
as ‘gold standard’ by some authors and is commonly 
prescribed in daily practice. 
Table 1. Drug Therapy for Alzheimer’s Disease
Acetylcholinesterase Inhibitors (AChEI)
Donepezil 
(pill or 
orodispersible 
tablets)
• Start with 5 mg once daily, then increase to 
10 mg/d after 4 to 6 weeks. If tolerate after 
>3 months of 10 mg/d, may gradually step up 
to 23 mg/d when there are further cognitive 
deterioration and/or functional decline
Rivastigmine • Pill: start with 1.5 mg twice daily initially, then 
titrate by 1.5 mg every 4 weeks up to 6 mg twice 
daily
• Patch: start with 4.6 mg/24 h, then 9.5 mg/24 h 
after 4 weeks. If tolerate after >6 months of 9.5 
mg/24 h, may step up to 13.3 mg/24 h when 
there are further cognitive deterioration and/or 
functional decline
Galantamine ER • Start with 8 mg daily, titrate by 8 mg/d every 4 
weeks up to 24 mg/d 
NMDA Receptor Antagonists
Memantine • Start with 5 mg/d, then increase by 5 mg every 1 
to 2 week up to 20 mg/d
Non-pharmacological Interventions
For the Patient
The list of non-pharmacological interventions that has 
been developed is long. Evidence is accumulating 
particularly regarding the efficacy of the more commonly 
used therapies.12-15 
 
Cognitive stimulation is by far showing the strongest 
evidence in efficacy. The intervention typically involves 
engaging in a range of enjoyable activities that require 
cognit ive processing within a group-based social 
context. There is evidence of cognitive, quality of life 
and wellbeing benefits.14 The cognitive enhancing effect 
is similar to pharmacological treatment16 and appears 
to add onto the benefits of AChEI.17 The UK National 
Institute for Health and Care Excellence (NICE) and 
Social Care Institute for Excellence (SCIE) Guideline 
recommends offering the intervention to all patients with 
mild-to-moderate dementia irrespective of their medical 
treatment.18
Structured cognitive training has not been associated 
with cognitive benefits, in particular benefits beyond 
the specific tasks trained. More individualized cognitive 
rehabilitation showed some promise, but evidence is 
currently limited. There is limited evidence to support 
cognitive effects of reminiscence therapy.16, 18
Exercise programmes appear to improve cognitive 
functioning and activities of daily living in people with 
dementia.15 Current evidence is insufficient to allow 
recommendation on specif ic programme designs, 
such as the type (e.g., aerobic, resistance, balance) of 
exercise. Possible mechanisms include neuroprotective 
neurotrophic factors, neuroplasticity, and reduction of 
cerebrovascular burden.19 Patients at different stage of 
dementia are capable of taking part in physical activity 
interventions, also for the associated strength, balance, 
and mobility benefits.16,20 Continued moderate-intensity 
physical exercise should be considered as an important 
therapeutic strategy. 
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For the Caregiver
Dementia inflicts on both the patient and the family 
caregivers. Due to its effects on the patient’s self-
care ability and the losses for caregivers that can be 
compared to bereavement, dementia caregivers are 
at risk of poor physical health, depression, anxiety 
burnout, and increased mortality.21,22 These contribute 
to unnecessary or premature institutionalization of the 
patient.23 
Multicomponent interventions targeting caergivers 
r e d u c e  b u r d e n  a n d  d e p r e s s i o n  a n d  d e l a y 
institutionalization, mainly through reduced frequency 
and severity of behavioural and psychological symptoms 
of dementia (BPSD).24 Successful interventions typically 
last about nine to 12 tai lored sessions del ivered 
individually over 3 to 6 months with regular follow-
up. Examples include the Resources for Enhancing 
Alzheimer’s Caregiver Health (REACH) in the US25 and 
the STrAtegies for RelaTives (START) study in the UK.26 
The former has been piloted in Hong Kong.27
For Both Patient and Caregiver
The Alzheimer’s Disease International (ADI) noted in its 
2011 report that successful interventions involve both 
the patient and the caregiver.16 These interventions 
should target family needs on educational information, 
emotional support, pract ical advice on disabi l i ty 
benefits, financial and legal issues started early in the 
disease course. 
 
Existing programmes mainly involve case management 
approaches with initial evidence for improved outcomes. 
However, there was large variation in protocols, and few 
programmes were specifically tailored for families facing 
early dementia.16 Programmes with a high degree of 
integration between health and social care providers are 
particularly beneficial.28 
Recent l y , the Hong Kong A lzhe imer ’s D isease 
Assoc ia t ion (HKADA) and ADI co-deve loped in 
collaboration with The University of Hong Kong the 
curriculum of Certificate Dementia Care Planner (CDCP), 
with a family focus and comprehensive advance care 
planning element, targeting to help families once a 
diagnosis is made. CDCPs have a role similar to a case 
manager but equipped with comprehensive knowledge 
of all aspects of dementia care, including mental and 
physical health, social, legal, financial, advance planning 
and environmental design.
Integrated Multidisciplinary Community 
Strategies
Dementia is a complex disorder affecting both the 
patients and their caregivers. Its management requires 
integrated mult idiscipl inary strategies. The DSM-
5 proposes a bio-psycho-social-cultural approach;29 
a compatible community model puts emphases in a 
reverse order and entails: 
1) Cultural: Development of a dementia-fr iendly 
community, in which dementia should be every 
family’s business;
2) Social: Provision of supportive programmes in the 
community (e.g., day centres), and mainstreaming 
dementia care into social services;
3) Psychological: Facilitate positive caregiving with a 
person-centred approach, including individualized 
advance care planning; and
4) Biological: Early diagnosis and treatment to reduce 
hospital admission and stay due to crisis. 
In line with this, local efforts have been made:
1) Public awareness in the community, including a 
collaborative destigmatization initiative by 10 NGOs 
and five colleges of the Hong Kong Academy of 
Medicine to revise the Chinese term for dementia;30
2) Dementia day centres and other community-based 
services, including the development of a culturally 
appropriate framework (the Chinese Six Arts) for 
multimodal non-pharmacological intervention, 
incorporating cognitive stimulation and physical 
activities for delivery in day centres; 
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3) Comprehens ive fami ly suppor t programme 
with knowledge, counselling, care coordination 
and advance care planning through training of 
CDCPs, who work with dementia care specialists 
and families with dementia to design conducive 
care plan, arrange necessary services, monitor 
intervention outcome, and help the family to make 
informed decisions about their future care while 
they still have the capacity; 
4) Pre-consultat ion assessment to tr iage help-
seekers and facil itate timely diagnosis, which 
involves trained allied healthcare professionals 
and pr imary care doctors in ear ly detect ion, 
early diagnosis and treatment programmes with 
specialist support. 
Best care for dementia mandate health and social 
services, drawing on the combined knowledge and 
evidence base of both systems.18 Primary care doctors 
have a pivotal role in the best practice of dementia care 
by connecting with the family for medico-social support 
in the locality. 
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Answer these on page 21 or make an online submission at: www.hkmacme.org
Please indicate whether the following statements are true or false.
1) Disease-modifying agents are available for use in AD.
2) Treatment of neuropsychiatric symptoms is mandatory in all patients.
3) Pharmacological treatment is equally important as non-pharmacological 
treatment.
4) ChEIs should be stopped once the patient enters into severe stage.
5) ChEIs have no effects on ADL function.
6) Memantine antagonist can be used for all causes of dementia.
7) Cognitive stimulation is effective in maintaining cognition in mild-to-moderate 
dementia.
8) Cognitive stimulation should not be used in combination with AChEIs.
9) Physical exercise should not be recommended in moderate-to-severe 
dementia.
10) Multi-component caregiver interventions may improve caergivers through 
reducing BPSD in the patient.
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